Composition to protect a mammal against Bartonella henselae infection
AssigneesHeska Corporation, Avant Immunotherapeutics, Inc., The United States of America as represented by the Department of Health and Human Services
InventorsRussell L. Regnery, Jane A. Rooney, Sharon A. Jenkins
Life of this patent
Estimating the term…
Abstract
The present invention relates to a therapeutic composition to protect a mammal from B. henselae infection that includes an isolated B. henselae antigen and an adjuvant comprising a phosphazene polymer. Also included is a method to use such a therapeutic composition to protect a mammal from B. henselae infection. One embodiment is a method to protect a human from cat scratch disease by administering such a therapeutic composition to a domestic cat in contact with the human. The present invention also includes a method to produce such a therapeutic composition.
Claims36
A therapeutic composition to protect a mammal from Barionella henselae (B. henselae) infection, said composition comprising:
- (a) an isolated B. henselae antigen comprising whole inactivated B. henselae cells;
- and
- (b) an adjuvant comprising poly(di(carboxylatophenoxv)phosphazene) (PCPP).
A method to protect a mammal from B. henselae infection comprising administering to said mammal a therapeutic composition comprising:
- (a) an isolated B. henselae antigen comprising whole inactivated B. henselae cells;
- and
- (b) an adjuvant comprising PCPP.
A method to protect a human from cat scratch disease comprising administering to a domestic cat in contact with said human a therapeutic composition comprising:
- (a) an isolated B. henselae antigen comprising whole inactivated B. henselae cells;
- and
- (b) an adjuvant comprising PCPP.
A method to produce a therapeutic composition to protect a mammal from B. henselae infection comprising the steps of:
- (a) growing B. henselae cells;
- (b) preparing an isolated B. henselae antigen comprising whole inactivated B. henselae cells from said cells;
- and
- (c) mixing said isolated B. henselae antigen with an adjuvant comprising PCPP.
Dependencies are inferred from the claim text.